$1.44
-0.06 (-4.00%)
Open$1.50
Previous Close$1.50
Day High$1.53
Day Low$1.43
52W High$4.19
52W Low$1.09
Volume—
Avg Volume277.7K
Market Cap100.02M
P/E Ratio—
EPS$-2.98
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,011.1% upside
Current
$1.44
$1.44
Target
$30.40
$30.40
$22.94
$30.40 avg
$39.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.52M | 24.88M | 53.29M |
| Net Income | -192,914,628 | -1,320,959,060 | -9,463,863 |
| Profit Margin | -3,492.3% | -5,603.4% | -17.8% |
| EBITDA | -139,056,342 | -1,395,170,020 | -11,859,784 |
| Free Cash Flow | — | — | -9,841,834 |
| Rev Growth | +183.3% | -45.3% | -6.8% |
| Debt/Equity | 10.79 | 2.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |